Analysts await Aratana Therapeutics, Inc. (NASDAQ:PETX) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.39 EPS, down 23.08% or $0.09 from last year’s $-0.3 per share.

At the moment 8 analysts are watching Aratana Therapeutics, Inc. (NASDAQ:PETX), 3 rate it “Buy”, 4 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 5 analysts have a mean sales target of 1.23 million. For the quarter ending Jun-16, 5 analysts have a mean sales target of 1.61 million whilst for the year ending Dec-16, 8 analysts have a mean target of 7.30 million.

In terms of earnings per share, 6 analysts have a -0.40 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 6 analysts have a -0.41 EPS mean target and for the quarter ending Jun-16 there are 8 estimates of -1.42 EPS.

The biggest institutional shareholders in Aratana Therapeutics, Inc. include Franklin Advisers, Inc. which owns 4 million shares in the company valued at $24.46 million. Wellington Management Company LLP is the second biggest holder with 4 million shares currently valued at 73.85 million whilst Jennison Associates LLC has 4 million shares valued at 22.42 million.

Total shares held by institutions as of the most recent company filings are 37,256,467 with a reported 5,564,577 bought and 3,336,274 sold. These holdings make up 81.58% of the company’s outstanding shares.

Currently insiders hold 1,644,225 shares in the business which makes up 4.70% of shares. The biggest holder currently is St Peter Steven who owns 792,793 shares (2.26% of those outstanding), whilst Dr. Linda Rhodes,PhD holds 423,205 (1.21% of shares outstanding) and Julia A. Stephanus holds 157,503 (0.45% of shares outstanding).

The stock increased 11.98% or $0.46 during the last trading session.